ES2779977T3 - Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana - Google Patents

Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana Download PDF

Info

Publication number
ES2779977T3
ES2779977T3 ES15759938T ES15759938T ES2779977T3 ES 2779977 T3 ES2779977 T3 ES 2779977T3 ES 15759938 T ES15759938 T ES 15759938T ES 15759938 T ES15759938 T ES 15759938T ES 2779977 T3 ES2779977 T3 ES 2779977T3
Authority
ES
Spain
Prior art keywords
hil
binding
seq
nmol
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15759938T
Other languages
English (en)
Spanish (es)
Inventor
Onur Boyman
Natalia Arenas-Ramirez
Chao Zou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Application granted granted Critical
Publication of ES2779977T3 publication Critical patent/ES2779977T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES15759938T 2014-07-10 2015-07-10 Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana Active ES2779977T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14176619 2014-07-10
PCT/IB2015/055226 WO2016005950A1 (en) 2014-07-10 2015-07-10 Immune-stimulating monoclonal antibodies against human interleukin-2

Publications (1)

Publication Number Publication Date
ES2779977T3 true ES2779977T3 (es) 2020-08-21

Family

ID=51162588

Family Applications (2)

Application Number Title Priority Date Filing Date
ES15759938T Active ES2779977T3 (es) 2014-07-10 2015-07-10 Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana
ES20158066T Active ES2989669T3 (es) 2014-07-10 2015-07-10 Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES20158066T Active ES2989669T3 (es) 2014-07-10 2015-07-10 Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana

Country Status (9)

Country Link
US (2) US10894828B2 (cg-RX-API-DMAC7.html)
EP (2) EP3166973B1 (cg-RX-API-DMAC7.html)
JP (1) JP7209464B2 (cg-RX-API-DMAC7.html)
CN (1) CN106604932B (cg-RX-API-DMAC7.html)
AU (1) AU2015287227B2 (cg-RX-API-DMAC7.html)
CA (1) CA2954476C (cg-RX-API-DMAC7.html)
DK (1) DK3166973T3 (cg-RX-API-DMAC7.html)
ES (2) ES2779977T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016005950A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL260218B2 (en) * 2016-01-11 2023-04-01 Novartis Ag Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins
EP3518969A2 (en) 2016-09-28 2019-08-07 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
GB201621806D0 (en) * 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
EP3585404A4 (en) * 2017-02-23 2021-04-14 City of Hope METHODS OF IN VIVO EXPANSION OF CD8 + T-LYMPHOCYTES AND PREVENTION OR TREATMENT OF GRAFT HOST REACTION (GVHD)
EA201992248A1 (ru) * 2017-03-23 2020-02-06 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания АНТИ-C5a-АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
RU2745451C1 (ru) * 2017-05-25 2021-03-25 Инститьют Фор Бейсик Сайенс Антитела к человеческому интерлейкину-2 и их применение
CN112020510B (zh) 2018-03-19 2024-10-11 茂体外尔公司 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
EP4090377A1 (en) 2020-01-13 2022-11-23 Synaffix B.V. Conjugates of antibodies an immune cell engagers
EP4103607A4 (en) * 2020-02-16 2023-12-20 Aulos Bioscience, Inc MODIFIED ANTI-IL-2 ANTIBODIES
AU2021327147A1 (en) * 2020-08-18 2023-04-06 Universität Zürich A CD25-biased anti-IL-2 antibody
CN117157107A (zh) 2021-02-08 2023-12-01 西纳福克斯股份有限公司 多功能抗体
KR20240082411A (ko) 2021-10-14 2024-06-10 라띠콘 (수저우) 바이오파마슈티칼스 코., 엘티디. 신규 항체-사이토카인 융합 단백질, 이의 제조 방법 및 이의 용도
US11773160B1 (en) 2022-08-05 2023-10-03 Anaveon AG Immune-stimulating IL-2 fusion proteins
CN119775409B (zh) * 2025-03-05 2025-07-11 深圳真实生物医药科技有限公司 靶向sost的抗体及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340853C (en) * 1983-12-23 1999-12-21 Hsiang-Fu Kung Purification of recombinant interleukin-2
JPS62269698A (ja) * 1986-03-17 1987-11-24 エフ．ホフマン　―　ラ　ロシュ　アーゲー Ｉｌ−２蛋白質に対するモノクロ−ナル抗体
CA2263129C (en) 1996-08-16 2007-01-09 Schering Corporation Mammalian cell surface antigens; related reagents
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
ATE386802T1 (de) 1997-06-12 2008-03-15 Novartis Int Pharm Ltd Künstliche antikörperpolypeptide
WO2004060319A2 (en) 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
NZ563213A (en) * 2005-06-01 2009-07-31 Micromet Ag Anti-IL2 antibodies
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
JP2009527500A (ja) * 2006-02-16 2009-07-30 ナセント・バイオロジックス・インコーポレイテッド 免疫機能を改善するための方法および哺乳動物対象における疾患の防止または処置のための方法
CN101045923B (zh) * 2006-03-31 2011-11-23 沈阳三生制药有限责任公司 生产一种白细胞介素类似物的方法
BRPI0907718A2 (pt) 2008-02-11 2017-06-13 Curetech Ltd método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento
SI3042917T1 (en) 2010-08-12 2018-04-30 Eli Lilly And Company Anti-n3pglu amyloid beta peptide antibodies and uses thereof
HUE040326T2 (hu) 2011-02-10 2019-03-28 Roche Glycart Ag Mutáns interleukon-2 polipeptidek
WO2013157105A1 (ja) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
WO2015109212A1 (en) * 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof

Also Published As

Publication number Publication date
JP7209464B2 (ja) 2023-01-20
WO2016005950A1 (en) 2016-01-14
EP3693389C0 (en) 2024-09-04
CN106604932B (zh) 2024-12-10
CA2954476A1 (en) 2016-01-14
US10894828B2 (en) 2021-01-19
EP3166973A1 (en) 2017-05-17
EP3693389B1 (en) 2024-09-04
AU2015287227A1 (en) 2017-02-09
US20170183403A1 (en) 2017-06-29
US20210230269A1 (en) 2021-07-29
EP3166973B1 (en) 2020-02-19
DK3166973T3 (da) 2020-04-06
JP2017525343A (ja) 2017-09-07
EP3693389A1 (en) 2020-08-12
EP3693389A9 (en) 2021-04-07
CN106604932A (zh) 2017-04-26
AU2015287227B2 (en) 2021-02-18
ES2989669T3 (es) 2024-11-27
CA2954476C (en) 2023-09-19
AU2015287227A8 (en) 2017-02-16

Similar Documents

Publication Publication Date Title
ES2779977T3 (es) Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana
JP7562528B2 (ja) 抗体及びその用途
ES2857813T3 (es) Anticuerpos anti pd-1 y anti-lag3 para el tratamiento del cáncer
TWI878430B (zh) 新型多肽複合物
ES2952132T3 (es) Nuevo anticuerpo anti-pad4
ES2719084T3 (es) Anticuerpo monoclonal para antagonizar e inhibir la unión de factor de crecimiento celular endotelial vascular y su receptor, y secuencia de codificación y uso de este
CN110914304A (zh) Cd96抗体、其抗原结合片段及医药用途
JP7430924B2 (ja) 拮抗的抗原結合タンパク質
Lu et al. Frontier of therapeutic antibody discovery: The challenges and how to face them
BR112019022702A2 (pt) gama de anticorpos anti-interferon e utilizações dos mesmos.
CN111148759A (zh) 结合至纤维连接蛋白b结构域的蛋白
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
WO2023125888A1 (zh) 一种gprc5d抗体及其应用
CA3180188A1 (en) Anti-flt3 antibodies and compositions
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
CN111788229A (zh) Csf1r结合剂
Zhao et al. Generation of anti-idiotype scFv for pharmacokinetic measurement in lymphoma patients treated with chimera anti-CD22 antibody SM03
ES2907717T3 (es) Proteínas y usos
CN115210263A (zh) 抗axl抗体和组合物
WO2024017326A1 (zh) 抗gprc5d纳米抗体及其应用
CN115335402B (zh) 特异性抗原结合分子,其制备方法及医药用途
CN118215685A (zh) 抗gucy2c抗体及其应用
RU2837590C1 (ru) Антитела против axl и композиции
RU2837590C9 (ru) Антитела против axl и композиции
McCue Engineering Tumor-Selective T Cell Engager Prodrugs for Cancer Immunotherapy